Sara J. Meltzer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sara J. Meltzer has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Kaberi Dasgupta
Department of Medicine McGill University Montreal Quebec Canada
4 shared publications - Natasha Garfield
Department of Medicine, Division of Adult Endocrinology and Metabolism, McGill University Health Centre , Montreal, QC H4A 3J1
3 shared publications - Deborah Da Costa
Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, QC, Canada
2 shared publications - Aaron Leong
Division of Clinical Epidemiology, Department of Medicine, McGill University Health Centre, 687 Pine Avenue West, H3A 1A1, Montreal, Quebec, Canada
1 shared publication - Agnieszka Majdan
Division of Endocrinology and Metabolism, Department of Medicine, Jewish General Hospital, Montreal, QC, Canada
1 shared publication - Alice Y. Y. Cheng
Trillium Health Partners and Unity Health University of Toronto Toronto Ontario Canada
1 shared publication
Latest Publications
- Open Access
- 3 November 2025
- Published by Elsevier in Canadian Journal of Diabetes
- Vol. 50 (1) , 47-54.e1
Lowering the Diagnostic Threshold for Gestational Diabetes: A Comparison of 2 Centres
- 3 November 2025
- Published by Elsevier in Canadian Journal of Diabetes
- Vol. 50 (1) , 47-54.e1
Open AccessLowering the Diagnostic Threshold for Gestational Diabetes: A Comparison of 2 Centres
- Open Access
- 4 February 2021
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 18 (4) , 1454
Trends in National Canadian Guideline Recommendations for the Screening and Diagnosis of Gestational Diabetes Mellitus over the Years: A Scoping Review
Canada’s largest national obstetric and diabetology organizations have recommended various algorithms for the screening of gestational diabetes mellitus (GDM) over the years. Though uniformity across recommendations from clinical practice guidelines (CPGs) is desirable, historically, national guidelines from Diabetes Canada (DC) and the Society of Obstetricians and Gynaecologists of Canada (SOGC) have differed. Lack of consensus has led to variation in screening approaches, rendering precise ascertainment of GDM prevalence challenging. To highlight the reason and level of disparity in Canada, we conducted a scoping review of CPGs released by DC and the SOGC over the last thirty years and distributed a survey on screening practices among Canadian physicians. Earlier CPGs were based on expert opinion, leading to different recommendations from these organizations. However, as a result of the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study, disparities between DC and the SOGC no longer exist and many Canadian physicians have adopted their recent recommendations. Given that Canadian guidelines now recommend two different screening programs (one step vs. two step), lack of consensus on a single diagnostic threshold continues to exist, resulting in differing estimates of GDM prevalence. Our scoping review highlights these disparities and provides a step forward towards reaching a consensus on one unified threshold.
- 4 February 2021
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 18 (4) , 1454
Open AccessTrends in National Canadian Guideline Recommendations for the Screening and Diagnosis of Gestational Diabetes Mellitus over the Years: A Scoping Review
Canada’s largest national obstetric and diabetology organizations have recommended various algorithms for the screening of gestational diabetes mellitus (GDM) over the years. Though uniformity across recommendations from clinical practice guidelines (CPGs) is desirable, historically, national guidelines from Diabetes Canada (DC) and the Society of Obstetricians and Gynaecologists of Canada (SOGC) have differed. Lack of consensus has led to variation in screening approaches, rendering precise ascertainment of GDM prevalence challenging. To highlight the reason and level of disparity in Canada, we conducted a scoping review of CPGs released by DC and the SOGC over the last thirty years and distributed a survey on screening practices among Canadian physicians. Earlier CPGs were based on expert opinion, leading to different recommendations from these organizations. However, as a result of the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study, disparities between DC and the SOGC no longer exist and many Canadian physicians have adopted their recent recommendations. Given that Canadian guidelines now recommend two different screening programs (one step vs. two step), lack of consensus on a single diagnostic threshold continues to exist, resulting in differing estimates of GDM prevalence. Our scoping review highlights these disparities and provides a step forward towards reaching a consensus on one unified threshold.
- Open Access
- 2 May 2018
- Published by Springer Nature in BMC Public Health
- Vol. 18 (1) , 575
Health behaviour changes in partners of women with recent gestational diabetes: a phase IIa trial
We recently demonstrated that a gestational diabetes history in mothers is associated with higher postpartum incident diabetes not only in mothers but also in fathers. In the present study, we examined changes in health behaviours and cardiometabolic profiles in both mothers and partners who participated in a diabetes prevention program within 5 years of a gestational diabetes pregnancy. Couples were enrolled into a 13-week program that included 5 half-day group sessions and web/telephone-based support between sessions. It was designed in consultation with patients and previously studied in mothers. We computed mean changes from baseline (95% CI) for physical activity, eating, and sleep measures, and cardiometabolic parameters (fasting and 2-h post glucose load plasma glucose, BMI, blood pressure) in both partners and mothers. Among 59 couples enrolled, 45 partners (76%) and 47 mothers (80%) completed final evaluations. Baseline cardiometabolic measures averaged within normal limits. Similar to mothers, partners increased physical activity (+ 1645 steps/day, 95%CI 730, 2561; accelerometer assessed moderate-to-vigorous physical activity + 36.4 min/week, 95% CI 1.4, 71.4) and sleep duration (+ 0.5 h/night, 95% CI 0.1, 0.9) and reduced the sodium-to-potassium ratio of food intake (− 0.09 95% CI -0.19, − 0.001). No conclusive changes were observed in glucose measures or insulin resistance; in analyses combining mothers and partners, systolic blood pressure decreased (− 2.7 mmHg, 95% CI -4.4, − 1.0). Partners and mothers demonstrated improved physical activity, sleep, and dietary quality. Baseline cardiometabolic profiles averaged at normal values and there were no changes in glucose or insulin resistance; some blood pressure impact was observed. While strategies need to be developed to attract participants at higher cardiometabolic risk, this study demonstrates that partners of women within 5 years of a gestational diabetes diagnosis can be recruited and do achieve health behaviour change. ClinicalTrials.gov: NCT02343354 (date of registration: January 22, 2015).
- 2 May 2018
- Published by Springer Nature in BMC Public Health
- Vol. 18 (1) , 575
Open AccessHealth behaviour changes in partners of women with recent gestational diabetes: a phase IIa trial
We recently demonstrated that a gestational diabetes history in mothers is associated with higher postpartum incident diabetes not only in mothers but also in fathers. In the present study, we examined changes in health behaviours and cardiometabolic profiles in both mothers and partners who participated in a diabetes prevention program within 5 years of a gestational diabetes pregnancy. Couples were enrolled into a 13-week program that included 5 half-day group sessions and web/telephone-based support between sessions. It was designed in consultation with patients and previously studied in mothers. We computed mean changes from baseline (95% CI) for physical activity, eating, and sleep measures, and cardiometabolic parameters (fasting and 2-h post glucose load plasma glucose, BMI, blood pressure) in both partners and mothers. Among 59 couples enrolled, 45 partners (76%) and 47 mothers (80%) completed final evaluations. Baseline cardiometabolic measures averaged within normal limits. Similar to mothers, partners increased physical activity (+ 1645 steps/day, 95%CI 730, 2561; accelerometer assessed moderate-to-vigorous physical activity + 36.4 min/week, 95% CI 1.4, 71.4) and sleep duration (+ 0.5 h/night, 95% CI 0.1, 0.9) and reduced the sodium-to-potassium ratio of food intake (− 0.09 95% CI -0.19, − 0.001). No conclusive changes were observed in glucose measures or insulin resistance; in analyses combining mothers and partners, systolic blood pressure decreased (− 2.7 mmHg, 95% CI -4.4, − 1.0). Partners and mothers demonstrated improved physical activity, sleep, and dietary quality. Baseline cardiometabolic profiles averaged at normal values and there were no changes in glucose or insulin resistance; some blood pressure impact was observed. While strategies need to be developed to attract participants at higher cardiometabolic risk, this study demonstrates that partners of women within 5 years of a gestational diabetes diagnosis can be recruited and do achieve health behaviour change. ClinicalTrials.gov: NCT02343354 (date of registration: January 22, 2015).
- 1 October 2017
- Published by Elsevier in Canadian Journal of Diabetes
- Vol. 41 (5) , 465-466
Choosing the Best Therapy for Your Patients in Today's Diabetes World
- 1 October 2017
- Published by Elsevier in Canadian Journal of Diabetes
- Vol. 41 (5) , 465-466
Choosing the Best Therapy for Your Patients in Today's Diabetes World
Unhealthy lifestyles and gestational diabetes
Another good reason for young women to quit smoking, eat better, and exercise
Unhealthy lifestyles and gestational diabetes
Another good reason for young women to quit smoking, eat better, and exercise
- Open Access
- 30 June 2014
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 13 (1) , 104
Group-based activities with on-site childcare and online support improve glucose tolerance in women within 5 years of gestational diabetes pregnancy
Women with gestational diabetes history are at increased risk for type 2 diabetes. They face specific challenges for behavioural changes, including childcare responsibilities. The aim of this study is to test a tailored type 2 diabetes prevention intervention in women within 5 years of a pregnancy with gestational diabetes, in terms of effects on weight and cardiometabolic risk factors.
- 30 June 2014
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 13 (1) , 104
Open AccessGroup-based activities with on-site childcare and online support improve glucose tolerance in women within 5 years of gestational diabetes pregnancy
Women with gestational diabetes history are at increased risk for type 2 diabetes. They face specific challenges for behavioural changes, including childcare responsibilities. The aim of this study is to test a tailored type 2 diabetes prevention intervention in women within 5 years of a pregnancy with gestational diabetes, in terms of effects on weight and cardiometabolic risk factors.
- 1 April 2014
- Published by Elsevier in Canadian Journal of Diabetes
- Vol. 38 (2) , 71-72
In-Hospital Diabetes Management
- 1 April 2014
- Published by Elsevier in Canadian Journal of Diabetes
- Vol. 38 (2) , 71-72
In-Hospital Diabetes Management
- Open Access
- 1 December 2010
- Published by American Diabetes Association in Diabetes Care
- Vol. 33 (12) , 2713-2715
Prepregnancy Care: A Shared Responsibility
- 1 December 2010
- Published by American Diabetes Association in Diabetes Care
- Vol. 33 (12) , 2713-2715
Open AccessPrepregnancy Care: A Shared Responsibility
- 26 January 2010
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 117 (4) , 407-415
Gestational diabetes mellitus screening and diagnosis: a prospective randomised controlled trial comparing costs of one‐step and two‐step methods
Please cite this paper as: Meltzer S, Snyder J, Penrod J, Nudi M, Morin L. Gestational diabetes mellitus screening and diagnosis: a prospective randomised controlled trial comparing costs of one‐step and two‐step methods. BJOG 2010;117:407–415.Objective To conduct a cost minimisation analysis of three methods of gestational diabetes mellitus (GDM) screening and diagnosis.Design Prospective randomised controlled trial.Setting University teaching hospital.Population Pregnant women (n = 1594) presenting for GDM screening.Methods Women presenting for GDM screening, who consented to participate, were randomised to GR1 [1‐hour, 50‐g glucose screen (GS) ± 3‐hour, 100‐g oral glucose tolerance test (OGTT)], GR2 (50‐g GS ± 2‐hour, 75‐g OGTT) or GR3 (2‐hour, 75‐g OGTT). Demographics, health and time/travel cost information were assessed for each glucose testing visit.Main outcome measures Costs (direct and indirect) and prevalence of GDM diagnosis.Results The direct sampling costs of the glucose tests per woman were as follows: GS, CAN$12.57; 75‐g OGTT, $36.10; 100‐g OGTT, CAN$48.13. Among women in the two‐step method groups diagnosed with GDM, 39% of the GR1 and 61% of the GR2 groups were diagnosed at the first step by GS ≥ 10.3 mmol/l, according to the Canadian Diabetes Association recommendations, contributing to a lower total cost in these groups. The total costs per woman screened were as follows: GR1, CAN$91.61; GR2, CAN$89.03; GR3, CAN$108.38. The GDM prevalence was similar (3.7%, 3.7% and 3.6%, respectively). The higher costs of GR3 were related to more blood draws and the time required for all women to undergo the 2‐hour OGTT.Conclusions Careful consideration should be given to an internationally recommended method of universal screening for GDM which minimises the burden and cost for individual women and the healthcare system, yet provides diagnostic efficacy. The two‐step method (GS ± OGTT) accomplished this better than the one‐step method (75‐g OGTT).
- 26 January 2010
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 117 (4) , 407-415
Gestational diabetes mellitus screening and diagnosis: a prospective randomised controlled trial comparing costs of one‐step and two‐step methods
Please cite this paper as: Meltzer S, Snyder J, Penrod J, Nudi M, Morin L. Gestational diabetes mellitus screening and diagnosis: a prospective randomised controlled trial comparing costs of one‐step and two‐step methods. BJOG 2010;117:407–415.Objective To conduct a cost minimisation analysis of three methods of gestational diabetes mellitus (GDM) screening and diagnosis.Design Prospective randomised controlled trial.Setting University teaching hospital.Population Pregnant women (n = 1594) presenting for GDM screening.Methods Women presenting for GDM screening, who consented to participate, were randomised to GR1 [1‐hour, 50‐g glucose screen (GS) ± 3‐hour, 100‐g oral glucose tolerance test (OGTT)], GR2 (50‐g GS ± 2‐hour, 75‐g OGTT) or GR3 (2‐hour, 75‐g OGTT). Demographics, health and time/travel cost information were assessed for each glucose testing visit.Main outcome measures Costs (direct and indirect) and prevalence of GDM diagnosis.Results The direct sampling costs of the glucose tests per woman were as follows: GS, CAN$12.57; 75‐g OGTT, $36.10; 100‐g OGTT, CAN$48.13. Among women in the two‐step method groups diagnosed with GDM, 39% of the GR1 and 61% of the GR2 groups were diagnosed at the first step by GS ≥ 10.3 mmol/l, according to the Canadian Diabetes Association recommendations, contributing to a lower total cost in these groups. The total costs per woman screened were as follows: GR1, CAN$91.61; GR2, CAN$89.03; GR3, CAN$108.38. The GDM prevalence was similar (3.7%, 3.7% and 3.6%, respectively). The higher costs of GR3 were related to more blood draws and the time required for all women to undergo the 2‐hour OGTT.Conclusions Careful consideration should be given to an internationally recommended method of universal screening for GDM which minimises the burden and cost for individual women and the healthcare system, yet provides diagnostic efficacy. The two‐step method (GS ± OGTT) accomplished this better than the one‐step method (75‐g OGTT).